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Extrahepatic portal vein thrombosis: aetiology and
determinants of survival
H L A Janssen, A Wijnhoud, E B Haagsma, S H M van Uum, C M J van Nieuwkerk,
R P Adang, R A F M Chamuleau, J van Hattum, F P Vleggaar, B E Hansen,
F R Rosendaal, B van Hoek
Abstract
Background—Malignancy, hypercoagula-
bility, and conditions leading to decreased
portal flow have been reported to contrib-
ute to the aetiology of extrahepatic portal
vein thrombosis (EPVT). Mortality of pa-
tients with EPVT may be associated with
these concurrent medical conditions or
withmanifestations of portal hypertension,
such as variceal haemorrhage.
Patients and methods—To determine
which variables have prognostic signifi-
cance with respect to survival, we per-
formed a retrospective study of 172 adult
EPVT patients who were followed over the
period 1984–1997 in eight university hospi-
tals.
Results—Mean follow up was 3.9 years
(range 0.1–13.1). Overall survival was 70%
(95% confidence interval (CI) 62–76%) at
one year, 61% (95% CI, 52–67%) at five
years, and 54% (95% CI, 45–62%) at 10
years. The one, five, and 10 year survival
rates in the absence of cancer, cirrhosis,
and mesenteric vein thrombosis were 95%
(95% CI 87–98%), 89% (95% CI 78–94%),
and 81% (95% CI 67–89%), respectively
(n=83). Variables at diagnosis associated
with reduced survival according to multi-
variate analysis were advanced age,
malignancy, cirrhosis, mesenteric vein
thrombosis, absence of abdominal inflam-
mation, and serum levels of aminotrans-
ferase and albumin. The presence of
variceal haemorrhage and myeloprolif-
erative disorders did not influence sur-
vival. Only four patients died due to
variceal haemorrhage and one due to
complications of a portosystemic shunt
procedure.
Conclusion—We conclude that mortality
among patients with EPVT is related
primarily to concurrent disorders leading
to EPVT and not to complications of por-
tal hypertension.
(Gut 2001;49:720–724)
Keywords: extrahepatic portal vein thrombosis; portal
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The occurrence of extrahepatic portal vein
thrombosis (EPVT) can be influenced by both
local and systemic aetiological factors. Local
factors comprise disorders leading to de-
creased portal flow such as liver cirrhosis and
hepatobiliary malignancies.1 2 Systemic risk
factors for EPVT consist mainly of acquired
and inherited abnormalities leading to hyper-
coagulability.3 The clinical outcome of EPVT
may be associated with these concomitant
medical conditions or with manifestations of
portal hypertension, in particular haemorrhage
from ruptured oesophageal varices. Due to the
rarity of the condition little is known about the
determinants of survival and causes of death of
patients with EPVT.4 The results of the few
published studies on the prognosis of EPVT
should be interpreted with caution as they
either consist of a small number of patients or
were performed in a highly selected population
of patients from endoscopic or surgical units.5 6
To investigate variables associated with survival
of EPVT, we undertook a retrospective analysis
of a large cohort of adult patients, recruited
from several medical disciplines.
Patients and methods
DESIGN OF THE STUDY
Patients were identified by means of a search in
the computerised hospital registration system of
all eight Dutch University Hospitals. All adult
patients registered with a diagnosis of EPVT
between January 1984 and July 1997 were
included in the study. For all patients a
standardised data form for specific clinical
information, and confirmation of the diagnosis,
was completed with data obtained from the
medical charts by one of the authors (HJ).
From a total of 236 patients thus identified with
EPVT, 22 were excluded from analysis because
the diagnosis was made at the postmortem
examination. Forty two patients were excluded
as they had been diagnosed prior to 1984.
Among the 172 patients in the cohort, follow up
lasted from the time of diagnosis to either
August 1997 or death, whichever came first. If
outcome was unknown, family physicians were
contacted. Five patients could not be traced and
were considered lost to follow up (3%). These
patients were censored from the analysis at the
last time point they were known to be alive. In
four cases liver transplantation was carried out
after the diagnosis of EPVT. For these patients
the date of transplantation was considered as
death due to liver failure. Separate analysis con-
sidering these four patients alive after transplan-
tation revealed no alteration in the variables
found to influence survival.
The following characteristics present at the
time of diagnosis were evaluated to determine
their prognostic significance for survival: age,
Abbreviations used in this paper: EPVT,
extrahepatic portal vein thrombosis.
Gut 2001;49:720–724720
Department of
Gastroenterology and
Hepatology, University
Hospital Rotterdam,
the Netherlands
H L A Janssen
A Wijnhoud
F P Vleggaar
Department of
Gastroenterology and
Hepatology, University
Hospital Groningen,
the Netherlands
E B Haagsma
Department of Internal
Medicine, University
Hospital St Radboud,
Nijmegen, the
Netherlands
S H M van Uum
Department of
Gastroenterology, Free
University Hospital,
Amsterdam, the
Netherlands
C M J van Nieuwkerk
Department of
Gastroenterology,
University Hospital
Maastricht, the
Netherlands
R P Adang
Department of
Gastroenterology,
Academic Medical
Centre, Amsterdam,
the Netherlands
R A F M Chamuleau
Department of
Gastroenterology,
University Hospital
Utrecht, the
Netherlands
J van Hattum
Department of Clinical
Epidemiology, Erasmus
University Rotterdam,
the Netherlands
B E Hansen
Department of Clinical
Epidemiology, Leiden
University Medical
Centre, the
Netherlands
F R Rosendaal
Department of
Gastroenterology and
Hepatology, Leiden
University Medical
Centre, the
Netherlands
B van Hoek
Correspondence to:
Dr H L A Janssen,
Department of
Gastroenterology and
Hepatology, Room Ca 326,
University Hospital
Rotterdam, Dr
Molewaterplein 40, 3015 GD
Rotterdam, the Netherlands.
devlaming@mdl.azr.nl
Accepted for publication
12 March 2001
www.gutjnl.com
 on 20 November 2006 gut.bmj.comDownloaded from 
sex, oesophageal varices, variceal haemorrhage,
ascites, hepatic encephalopathy, malignancy,
liver cirrhosis, myeloproliferative disorders,
mesenteric vein thrombosis, abdominal inflam-
mation as a cause of EPVT, and levels of
bilirubin, albumin, alanine aminotransferase,
haemoglobin, and platelets.
DIAGNOSTIC ASSESSMENT
Diagnostic criteria for EPVT were partial or
complete thrombotic obstruction of the extra-
hepatic portal vein, as documented by appro-
priate radiological abdominal imaging (that is,
Doppler ultrasonography, computed tomogra-
phy, magnetic resonance imaging, splenopor-
tography), or laparotomy. The presence of
oesophageal varices was evaluated by means of
endoscopy, which had been performed in 130
cases (76%). Patients with suspected variceal
bleeding underwent endoscopic examination
and, when indicated, sclerotherapy or band
ligation. Ascites was diagnosed by physical
examination and ultrasonography of the abdo-
men, which was carried out routinely. The
presence of cirrhosis had to be proved by liver
biopsy. A liver biopsy was obtained in 90
patients (52%). In more than 95% of the non-
biopsied patients, no radiological signs of
cirrhosis were found. Mesenteric vein throm-
bosis was defined as extensive thrombosis with
clinical signs of intestinal infarction. Thus an
asymptomatic thrombus limited to the conflu-
ent area of the superior mesenteric vein was not
considered mesenteric vein thrombosis. A
diagnosis of myeloproliferative disease was
confirmed by bone marrow examination in all
cases. Latent primary myeloproliferative disor-
der, as diagnosed by erythroid colony forma-
tion, was tested in a minority of patients and,
for the purpose of this study, not considered to
be a myeloproliferative disease. Standardised
screening for thrombophilia was performed in
a central laboratory for the 73 patients available
for blood sampling.7 This screening included
factor V Leiden mutation, prothrombin gene
mutation, and inherited deficiencies for protein
C, protein S, and antithrombin. Correction for
potential acquired deficiencies of these coagu-
lation inhibitors, as in liver failure, was done by
correction for factor II and factor X.8 As only
patients alive could be fully tested, throm-
bophilia was not included as a variable in the
survival analysis.
STATISTICAL ANALYSIS
Survival was calculated by the Kaplan-Meier
method. Duration of survival was determined
irrespective of the cause of death. For univari-
ate analysis, comparison of survival curves was
based on the log rank test. Multivariate analysis
was done by proportional hazard modelling.9
In order to avoid an excess of variables for the
multivariate analysis, both cirrhotic and non-
cirrhotic patients diagnosed with Budd-Chiari
syndrome were analysed as cirrhotics. The
proportional hazard assumption of the Cox
regression model was tested separately for each
variable extending the multivariate model with
a variable as a function of follow-up time—that
is, a time dependent variable. Furthermore,
interactions between explanatory variables
were tested.
Results
Risk factors for the development of EPVT in
the 172 investigated patients are shown in table
1. Systemic aetiological factors were present in
64 (37%) and local aetiological factors in 110
(64%) of the 172 patients. Coexistence of sys-
temic and local risk factors was demonstrated
in 28 (16%) patients while more than one risk
factor for EPVT, irrespective of whether they
were systemic or local, was found in 54 (31%)
patients. In 27 (16%) patients no risk factors
for EPVT were identified.
Median age at diagnosis was 51 years (range
14–91). Fifty per cent of patients were male and
more than 95% were Caucasian. An episode of
bleeding from ruptured oesophagogastric
varices was the initial manifestation in 52 (30%)
patients, 50 (96%) of whom underwent endo-
scopic treatment. Mean follow up time for the
172 patients was 3.9 years (range 0.1–13.1).
Sixty seven (39%) patients died during follow
Table 1 Risk factors of patients with extrahepatic portal vein thrombosis (n=172)
Risk factor n % Specification
Hepatic disorders 52 30 Cirrhosis (n=37), Budd-Chiari syndrome (n=12), nodular regenerative hyperplasia
(n=2), incomplete septal fibrosis (n=1)
Abdominal inflammation 30 17 Pancreatitis (n=11), liver abscess (n=7), inflammatory bowel disease (n=6), cholangitis
(n=3), umbilical vein infection (n=1), appendicitis (n=2)
Malignancies 41 24 Hepatocellular carcinoma (n=15), pancreatic carcinoma (n=6), biliary tract carcinoma
(n=3), other malignancy with liver metastases (n=6), other malignancy without liver
metastases (n=11)
Abdominal intervention 40 23 Hepatobiliary surgery (n=20), splenectomy (n=13), liver transplantation (n=3), jejunal
resection (n=2), abdominal trauma (n=2)
Hypercoagulability 47 27 Pregnancy (n=3), oral contraceptives (n=13), paroxysmal nocturnal haemoglobinuria
(n=4), antiphospholipid syndrome (n=6), systemic lupus erythematosus (n=2), factor
V Leiden mutation* (n=6), protrombin gene mutation* (n=3), protein C deficiency*
(n=7), protein S deficiency* (n=2), antithrombin deficiency* (n=1)
Myeloproliferative syndrome 24 14 Polycythemia vera (n=12), essential thrombocytosis (n=3), myelofibrosis (n=6),
myeloid leukaemia (n=1), unclassified (n=2)
Patients can have more than one risk factor.
*Only tested for patients from whom a blood sample could be obtained in July 1997 (n=73).
Table 2 Causes of death among 67 patients with
extrahepatic portal vein thrombosis
Cause of death n %
Hepatobiliary and gastrointestinal malignancies 18 27
Other malignancies 12 18
Liver failure 10 15
Cardiopulmonary disorders 9 13
Variceal bleeding 4 6
Infection 4 6
Postoperative complications 2 3
Other causes 5 8
Unknown 3 4
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up. The causes of death are listed in table 2.
Most patients died of (hepatobiliary) cancer and
liver failure. Variceal bleeding was the cause of
death in only four patients (2%). Among the 98
patients with non-malignant and non-cirrhotic
EPVT, two (2%) died of variceal haemorrhage.
Overall survival was 70% (95% confidence
interval (CI) 62–76%) at one year, 61% (95%
CI 52–67%) at five years, and 54% (95% CI
45–62%) at 10 years (fig 1). The survival rates
for EPVT patients without cancer and cirrhosis
and for those with either cirrhosis or cancer is
shown in fig 2. The one, five, and 10 year sur-
vival rates in the absence of cancer, cirrhosis,
and mesenteric vein thrombosis were 95%
(95% CI 87–98%), 89% (95% CI 78–94%),
and 81% (95% CI 67–89%), respectively
(n=83). From a total of 10 deaths in this group
of 83 patients, only one died of variceal bleed-
ing.
Patient characteristics at the time of diagno-
sis evaluated for their prognostic significance
are shown in table 3. Variables significantly
associated with reduced survival according to
the univariate analysis were advanced age,
cirrhosis, ascites, malignancy, absence of
oesophageal varices, absence of abdominal
inflammation, high levels of serum alanine
aminotransferase, and low levels of serum
albumin. Survival probability for patients with
concurrent mesenteric vein thrombosis was
markedly reduced but failed to reach signifi-
cance. Neither the occurrence of variceal
bleeding nor the presence of myeloproliferative
disorders at diagnosis influenced survival
significantly. The results of multivariate analy-
sis are presented for all investigated patients
(n=172) and for those with non-malignant
EPVT (n=131) in table 4. Age, absence of
abdominal inflammation, cirrhosis, malig-
nancy, mesenteric vein thrombosis, and serum
levels of alanine aminotransferase and albumin
had an independent prognostic value for
survival. Test for the proportional risk assump-
tions did not show any non-proportionalities.
Forty six (27%) of the 172 patients were
treated with anticoagulation at their last hospi-
tal visit. Many were treated intermittently dur-
ing follow up. Seventeen (10%) of the 172
patients underwent a procedure to reduce por-
tal hypertension. Fourteen had a portosystemic
shunt (mesocaval n=6, splenorenal n=5, trans-
jugular intrahepatic portosystemic shunt pro-
cedure n=3), one a thrombectomy, and two a
portal reconstruction for EPVT as a conse-
quence of liver transplantation. Median time
between diagnosis of EPVT and intervention
Figure 1 Actuarial survival of 172 patients with
extrahepatic portal vein thrombosis. Number of patients at
risk during follow up are shown along the x axis.
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Figure 2 Actuarial survival rates for patients with
extrahepatic vein thrombosis without cirrhosis and cancer
(patients at risk n=98, n=47, and n=17 after 0, 5, and 10
years of follow up, respectively), for patients with cirrhosis
but no cancer (patients at risk n=33, n=9, and n=3 after
0, 5 and 10 years of follow up, respectively), and for
patients with cancer (patients at risk n=41 and n=3 after 0
and 5 years of follow up, respectively).
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Table 3 Characteristics at diagnosis of patients with
extrahepatic portal vein thrombosis (n=172) and results of
univariate analysis
n
5 year
survival (%) p Value**
Age (y)
<40 48 83 <0.001
40–60 70 62
>60 54 39
Sex
Male 86 58 0.52
Female 86 63
Haemoglobin (mmol/l)
<7.5 76 58 0.51
>7.5 96 63
Platelet count (×109/l)
<170 84 56 0.26
>170 88 65
Alanine aminotransferase (U/l)
<30 93 75 <0.001
>30 79 43
Bilirubin (µmol/l)
<20 86 66 0.18
>20 86 55
Albumin (g/l)
<35 75 43 <0.001
>35 97 75
Oesophageal varices*
Absent 26 49 0.02
Present 104 70
Variceal bleeding
Absent 120 67 0.43
Present 52 58
Ascites
Absent 107 68 0.01
Present 65 48
Mesenteric vein thrombosis
Absent 153 62 0.08
Present 19 41
Cirrhosis
Absent 124 68 <0.001
Present 48 35
Myeloproliferative disease
Absent 148 56 0.12
Present 24 88
Malignancy
Absent 131 77 <0.001
Present 41 8
Abdominal inflammation
Absent 143 55 0.001
Present 29 92
*130 patients tested.
**Log rank test.
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was one month (range 0–62). Five of the 17
patients died during follow up: one postopera-
tively, two from recurrent variceal haemor-
rhage, and two from causes unrelated to EPVT.
For two of the deceased patients shunt
occlusion was documented.
Discussion
In this study we identified causative and
clinical factors that aVected the survival of
adult patients with EPVT. Previous studies on
the prognosis of EPVT are scarce and are con-
fined mainly to children or young adults with
non-malignant and non-cirrhotic portal vein
thrombosis.1 6 10 11 Many of these studies were
performed at a time when endoscopic therapy
was not yet available. Moreover, these studies
took place in single highly specialised hospital
units which focused on the benefit of portosys-
temic shunting. However, patients with EPVT
are encountered in several diVerent medical
disciplines and the present study was designed
to minimise patient selection.
Over the last two decades it has become
apparent that the aetiology of EPVT is highly
diverse. We found at least one risk factor for the
development of EPVT in 84% of patients. This
despite the fact that not all patients underwent
complete screening for hypercoagulability and
that latent myeloproliferative disorders were
not included as a risk factor. The occurrence of
umbilical vein infection as a cause for EPVT
was low as only newly diagnosed adult patients
were investigated. Coexistence of causative
factors was observed in about one third of
patients, indicating that thrombosis of the por-
tal vein, like other manifestations of thrombo-
sis, can be a result of combined pathogenetic
mechanisms.12 13 A combination of systemic
and local risk factors was found for 16% of the
population. This suggests that in some patients
genetic defects may create a predisposition for
thrombosis which leads to clinically manifest
EPVT in the presence of acquired thrombotic
stimuli, such as cirrhosis, pancreatitis, splenec-
tomy, and hepatobiliary surgery.7 14
An important finding of this study was the
fact that mortality among patients with EPVT
was related primarily to concurrent medical
conditions, which are often the cause of EPVT,
rather than to manifestations of portal hyper-
tension, such as variceal haemorrhage. Progno-
sis was excellent if EPVT occurred in the
absence of malignancy, cirrhosis, and me-
senteric vein thrombosis. Absence of oesopha-
geal varices was associated with a poor progno-
sis in the univariate analysis. This unexpected
finding can be explained by the fact that many
EPVT patients who suVered from life threaten-
ing diseases, such as cancer and mesenteric
vein thrombosis, did not have the life expect-
ancy to develop varices. The presence of
variceal bleeding at presentation did not influ-
ence survival, and fatal haemorrhages occurred
in only 2% of the investigated population. Even
among patients with non-malignant and non-
cirrhotic EPVT only 1% experienced fatal
variceal bleeding. On the one hand this finding
contrasts with previous prognostic studies on
EPVT in which variceal bleeding was held
responsible for the death of 15–25% of
patients.1 5 On the other hand it probably
underlines the eYcacy of endoscopic interven-
tion which was employed as firstline treatment
in 96% of our patients who presented with
variceal haemorrhage. The success of endo-
scopic therapy for EPVT induced bleeding
varices has already been documented. Groups
from India and the Netherlands reported a
negligible death probability due to recurrent
EPVT induced variceal bleeding five years after
sclerotherapy.15 16 Merkel et al found that in
comparison with patients with variceal bleed-
ing due to cirrhosis, the outcome of bleeding
for patients with non-cirrhotic EPVT was
significantly better.17 This phenomenon can be
explained by intact coagulation and liver func-
tion in patients with non-cirrhotic EPVT and
possibly by the development of porto-portal
collaterals which in time may stabilise portal
pressure.
Only 17 (10%) of our 172 patients under-
went a procedure to reduce portal hyper-
tension (portosystemic shunting, portal
thrombectomy, or portal reconstruction). Al-
though the low number of shunts is partly
related to the high prevalence of comorbidity in
our population, it may also indicate the eYcacy
of endoscopic treatment in the secondary pre-
vention of variceal bleeding. As most of the
shunted patients were highly selected, our data
were insuYcient to analyse whether portosys-
temic shunting could influence survival. Excel-
lent long term survival rates without occur-
rence of post-shunt encephalopathy have been
described for patients exclusively treated with
surgical shunts in the period prior to the intro-
duction of endoscopic treatment.11 18 19 How-
ever, randomised controlled studies are lacking
and the long survival found in some of these
studies could also be explained by selection of
patients without considerable comorbidity. We
also did not have the possibility of evaluating
whether anticoagulation is beneficial for pa-
tients with EPVT.20 21 About 25% of our
patients were treated with anticoagulation.
Most were treated intermittently during follow
up and in some no anticoagulation was given at
diagnosis. The prognostic eVect of both
anticoagulation and portosystemic shunting
should ideally be investigated in controlled
prospective studies.
Table 4 Variables significantly influencing survival according to multivariate analysis.
Relative risk (RR) of death is given for all investigated patients (n=172) and for those
with non-malignant extrahepatic portal vein thrombosis (EPVT) (n=131)
EPVT (n=172)
Non-malignant EPVT
(n=131)
RR 95% CI p Value RR 95% CI p Value
Age (y)
40–60 2.6 1.1–5.9 0.02 1.4 0.5–3.8 0.5
>60 5.8 2.5–13.2 < 0.001 5.3 1.9–14.7 < 0.001
Alanine aminotransferase>30 U/l 1.9 1.1–3.2 0.01 1.9 0.9–4.1 0.06
Albumin <35 g/l 3.2 1.8–5.8 0.001 3.9 1.9–8.2 < 0.001
Mesenteric vein thrombosis 2.9 1.4–5.9 0.003 7.4 2.7–20.1 < 0.001
Cirrhosis 3.9 1.9–8.1 0.002 4.9 2.2–10.9 < 0.001
Absence of abdominal inflammation 4.6 1.3–15.7 0.01 15.3 1.9–122.6 < 0.001
Malignancy 8.1 4.1–16.0 < 0.001 — — —
Survival in extrahepatic portal vein thrombosis 723
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In summary, our data indicate that the
outcome of EPVT is primarily associated with
concomitant diseases leading to EPVT and not
with bleeding from ruptured oesophageal
varices. Our findings support sclerotherapy or
band ligation as the primary treatment modal-
ity for variceal bleeding as a result of EPVT.
Portosystemic shunting should probably be
reserved for patients without important comor-
bidity who fail to respond to repeated endo-
scopic treatment.
We are indebted to SW Schalm and HR van Buuren
(Department of Hepatogastroenterology, University Hospital
Rotterdam), and to JP Vandenbroucke (Department of Clinical
Epidemiology, Leiden University Medical Centre) for their
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Gastroshunt Foundation.
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